Dechra Pharmaceuticals PLC Annual Report & Accounts for period ended 30 June 2013

Developing

Focusing

Delivering

Developing

the Business through Investment in our Pipeline

Find out more >

Focusing

on our Veterinary Pharmaceuticals Product Strategy

Find out more >

Delivering

Sustainable Growth and Value

Find out more >

Highlights

Highlights

Revenue

£ million

up 52.2%

Underlying Operating Profit*

£ million

up 53.1%

Underlying Profit Before Taxation*

£ million

up 53.7%

Underlying Earnings per Share*

pence

up 37.1%

Dividend per Share

pence

up14.1%

Operating Profit

£ million

up 78.5%

Profit Before Taxation

£ million

up 104.2%

Earnings per Share

pence

up 31.6%

Chairman's Statement

Chairman's Statement

Our European Pharmaceuticals Segment continues to show progress and achieved sales of £168.7 million, an increase of 66.3%.

More on Chairman's Statement

Operating Review

Overview

The sale of the Services business is a significant step forward in achieving our clearly defined strategic objective.

More on Operating Review

Financial Review

Financial Review

Our divestment of the Services Segment (announced on 10 July 2013) was a logical strategic step following the successful acquisition of Eurovet

More on Financial Review